Šw‰ï”­•\

 

 

ƒƒTƒ‹ƒ^ƒ“ƒJƒŠƒEƒ€‚ÌCaco-2×–E‚Ö‚ÌŽæ‚螂݂ɑ΂·‚éƒLƒgƒTƒ“‚̉e‹¿

‘æ27‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiç—tj@2017.11.5

Šâú±ˆ»”TA‰ª“cŒ·–çAˆ¢•”^—ŽqA¡ˆäŒö]

 

EGFR ˆâ“`Žq•ψٗz«”xŠà‚É‚¨‚¯‚éafatinib ‚Ì•êW’c–ò•¨“®‘Ô‰ðÍ

‘æ58‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ïi‰¡•lj@2017.10.14

’†”öŒjŽqA‹à’óŽ÷A“c‹{Šî—TAˆÉ²rˆêA“c‹{˜N—TA‘å’¬’¼Ž÷A‰«‰–‹¦ˆêAŠÛ’JŽü•½AŠâú±ˆ»”TA¡ˆäŒö]A‰ÍŸº^Ž¡A‰h“c•q”VA•½“‡’q“¿AˆÀ‘îM“ñ

 

ƒƒgƒzƒ‹ƒ~ƒ“‚ÌCaco-2×–E‚ł̖Œ—A‘—‚ɑ΂·‚éH•¨‘@ˆÛ‚̉e‹¿

ˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2017@‘æ25‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€iŽ­Ž™“‡j@2017.7.1

ŽR–{‰ê“Þ‰hAŠâú±ˆ»”TA¼ì®ŽqA‹àŽq˜ÐŽjA¡ˆäŒö]

 

ƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“¿Ü“Š—^ƒ‰ƒbƒg‚É‚¨‚¯‚éƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“‚ÌŒŒ’†”Z“x„ˆÚ

ˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2017@‘æ25‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€iŽ­Ž™“‡j@2017.7.1

ŽRŒûãÄ‘¾AŠâú±ˆ»”TA¡ˆäŒö]

 

ƒƒgƒzƒ‹ƒ~ƒ“‚ÌCaco-2×–E‚Ö‚ÌŽæ‚螂݂ɑ΂·‚éH•¨‘@ˆÛ‚̉e‹¿

“ú–{–òŠw‰ï‘æ137”N‰ïiå‘äj@2017.3.27

Šâú±ˆ»”TA¼ì®ŽqA¡ˆäŒö]

 

ƒWƒNƒƒtƒFƒiƒNƒiƒgƒŠƒEƒ€¿Ü‚©‚ç‚ÌŽå–ò—no«

“ú–{–òŠw‰ï‘æ137”N‰ïiå‘äj@2017.3.26

¡ˆäŒö]A’·‘©Ë•½AŠâú±ˆ»”T

 

EGFR •ψٗz«NSCLC‚ÌŠà«‘–Œ‰Š—á‚Ö‚ÌAfatinib‚Ì‘‰tˆÚs«‚Æ—LŒø«‚ÌŒŸ“¢

‘æ105‰ñ“ú–{”xŠàŠw‰ïŠÖ¼Žx•”ŠwpW‰ïi‘åãj 2017.2.25

’†”öŒjŽqA“c‹{˜N—TA’Ò@‘×—CA’|“à“ÞŽqAˆÉ²rˆêA‘å’¬’¼Ž÷A‰«‰–‹¦ˆêAˆÀ‘îM“ñA“c‹{Šî—TA‰ª–{‹I—YA—é–ØG˜aA•½“‡’q“¿AŠâú±ˆ»”TA¡ˆäŒö]

 

Efficacy and cerebrospinal fluid concentration of afatinib in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis

IASLC 17th World Conference on Lung CanceriVienna, Austriaj 2016.12.4-7

Akihiro Tamiya, Motohiro Tamiya, Takashi Nishihara, Takayuki Shiroyama, Keiko Nakao, Taisuke Tsuji, Naoko Takeuchi, Shun-ichi Isa, Naoki Omachi, Norio Okamoto, Hidekazu Suzuki, Ayano Iwazaki, Kimie Imai, Tomonori Hirashima, Shinji Atagi

 

ˆê”Ê—pˆã–ò•i‚̃AƒZƒgƒAƒ~ƒmƒtƒFƒ“¿Ü‚©‚ç‚ÌŽå–ò—no«

‘æ‚S‚X‰ñ“ú–{–òÜŽt‰ïŠwp‘å‰ïi–¼ŒÃ‰®j@2016.10.9

ŽRŒûãÄ‘¾A‘ºã³Ž÷AŠâú±ˆ»”TA¡ˆäŒö]

 

A pilot study of the cerebrospinal fluid  extraction rate and efficacy of afatinib in non-small cell lung cancer patients harboring epidermal growth factor receptor mutation  with carcinomatous meningitis

the European Society for Medical Oncology 2016 Congress@(Copenhagen, Denmark)@ 2016.10.7-11

Akihiro Tamiya, Motohiro Tamiya, Takashi Nishihara, Takayuki Shiroyama, Keiko Nakao, Taisuke Tsuji, Naoko Takeuchi, Shun-ichi Isa, Naoki Omachi, Norio Okamoto, Hidekazu Suzuki, Kyoichi Okishio, Ayano Iwazaki, Kimie Imai, Tomonori Hirashima, Shinji Atagi

 

‚މ–bHێ惉ƒbƒg‚ÌŠÌ‘Ÿd—Ê‚¨‚æ‚ÑŠÌ‘Ÿ’†‚̃RƒŒƒXƒeƒ[ƒ‹—Ê‘‰Á‚ɑ΂·‚éƒvƒ‰ƒoƒXƒ^ƒ`ƒ“‚¨‚æ‚уLƒgƒTƒ““Š—^‚̉e‹¿

‘æ26‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‹ž“sj@2016.9.18

Šâú±ˆ»”TA‹g–ì—S‘¾˜YA–î–ìL«A¡ˆäŒö]

 

ƒƒTƒ‹ƒ^ƒ“ƒJƒŠƒEƒ€‚ÌCaco-2×–E‚ł̖Œ—A‘—‚ɑ΂·‚éƒLƒgƒTƒ“‚̉e‹¿

“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•lj@2016.3.27

Šâú±ˆ»”TAˆÀˆäˆ¤—A¡ˆäŒö]

 

ƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“¿Ü‚©‚ç‚ÌŽå–ò•úo«‚Ì”äŠr

“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•lj@2016.3.27

¡ˆäŒö]A¼“cËŽjA‘ºã³Ž÷AŠâú±ˆ»”T

 

ŒŒ’†ƒRƒŒƒXƒeƒ[ƒ‹‹y‚ÑŠÌ‘Ÿd—ʂɑ΂·‚éƒvƒ‰ƒoƒXƒ^ƒ`ƒ“‚ƃLƒgƒTƒ“‚̉e‹¿

‘æ25‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‰¡•lj@2015.11.22

Šâú±ˆ»”TA•ÐŽR—Y‹MA–î–ìL«A‹g–ì—S‘¾˜YA¡ˆäŒö]

 

ƒƒTƒ‹ƒ^ƒ“ƒJƒŠƒEƒ€‚ÌCaco-2×–E‚Ö‚ÌŽæ‚螂݂ɑ΂·‚éƒLƒgƒTƒ“‚̉e‹¿

“ú–{–òŠw‰ï‘æ135”N‰ïi_ŒËj@2015.3.26

Šâú±ˆ»”TAœA“ˆ—DAˆ¢•”^—ŽqAˆÀˆäˆ¤—A¡ˆäŒö]

 

ƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“¿Ü‚ÌŽå–ò•úo«

“ú–{–òŠw‰ï‘æ135”N‰ïi_ŒËj@2015.3.26

¡ˆäŒö]A’†“‡ËA¼“cËŽjAŠâú±ˆ»”T

 

ƒƒTƒ‰ƒWƒ“‹y‚уoƒ‹ƒvƒŽ_‚̃Aƒ‹ƒMƒ“Ž_ƒiƒgƒŠƒEƒ€‚ɑ΂·‚é‹z’…

‘æ47‰ñ“ú–{–òÜŽt‰ïŠwp‘å‰ïiŽRŒ`j@2014.10.12-13

’·ˆäŽmA¬¼œAŒÈAŠâú±ˆ»”TA¡ˆäŒö]

 

“œ”A•aŽ¡—Öò‚Ìin vitro‚É‚¨‚¯‚é—V—£–ò•¨—ʂɑ΂·‚éH•¨‘@ˆÛ‚̉e‹¿

‘æ24‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi–¼ŒÃ‰®j@2014.9.27

Šâú±ˆ»”TA’†ì‚݂ȂÝA¡ˆäŒö]

 

Caco-2×–E‚É‚¨‚¯‚郃Tƒ‹ƒ^ƒ“‚Ì—A‘—‚ɑ΂·‚éH•¨‘@ˆÛ‚̉e‹¿

“ú–{–òŠw‰ï‘æ134”N‰ïiŒF–{j@2014.3.30

Šâú±ˆ»”TAŽO‘î—çŽqA¡ˆäŒö]A’†¼–M•v

 

‚ƒAƒ“ƒ‚ƒjƒAŒŒÇƒ‰ƒbƒg‚ɑ΂·‚élŽQƒWƒ…[ƒX‚̉e‹¿

‘æ23‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiå‘äj@2013.9.22

¡ˆäŒö]Aˆî—t–ƒˆßA‹´“c’m‰ÂŽqAŠâú±ˆ»”TA’†¼–M•vAã–ìŽRŽü—Y

 

H•¨‘@ˆÛ‚É‚æ‚éƒrƒOƒAƒiƒCƒhŒn“œ”A•aŽ¡—Öò‚Ìin vitro‚É‚¨‚¯‚é—V—£–ò•¨—ʂ̒ቺ

‘æ23‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiå‘äj@2013.9.21

Šâú±ˆ»”TA’†ì‚݂ȂÝA¡ˆäŒö]A’†¼–M•v

 

ƒ¿|ƒŠƒ|Ž_‹y‚Ñ‚»‚̃Á|CD•¡‡‘̂̃‰ƒbƒgˆÝ”S–Œ‹y‚Ѭ’°–Œ“§‰ß«‚ɂ‚¢‚Ä

‘æ30‰ñƒVƒNƒƒfƒLƒXƒgƒŠƒ“ƒVƒ“ƒ|ƒWƒEƒ€iŒF–{j@2013.9.13

’†¼–M•vAå@—C”nAŠâú±ˆ»”TA¡ˆäŒö]A¶“c’¼ŽqA‰ª–{—zØŽqA’†“c‘å‰îAŽ›”öŒ[“ñ

 

ˆê”Ê—pˆã–ò•i‚̈ݒ°–ò‚É‚¨‚¯‚é§Ž_—͂̔äŠrŒŸ“¢

‘æ21‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€i‹à‘òj@2013.7.20

’Ò@–¾OAŠâú±ˆ»”TA¡ˆäŒö]A’†¼–M•v

 

ŠÌ޾гޡ—ÖòƒOƒŠƒ`ƒ‹ƒŠƒ`ƒ“‚̃‰ƒWƒJƒ‹‚Ƃ̔½‰ž«

“ú–{–òŠw‰ï‘æ133”N‰ïi‰¡•lj@2013.3.30

¡ˆäŒö]Aˆäã’m”üA‚–Ø—EŽuA–îã’m‰ÀAŠâú±ˆ»”TA’†¼–M•v

 

“ú–{‚É—¬’Ê‚·‚é”’‹àR‚ª‚ñ܂̃oƒCƒAƒ‹•\–ʉ˜õ‚Ì”äŠr

“ú–{–òŠw‰ï‘æ133”N‰ïi‰¡•lj@2013.3.29

“à“¡—²•¶A‘åàV—²ŽuA—é–Ø’¼ÆAŒã“¡•q–çA‚“c WA’†“¹G“¿A‘åŠÑ‚悵ŽqA¡ˆäŒö]A’†¼–M•vAìトê

 

ƒƒTƒ‹ƒ^ƒ“ƒJƒŠƒEƒ€‚Ì×–E‚Ö‚ÌŽæ‚螂݂ɑ΂·‚éH•¨‘@ˆÛ‚̉e‹¿

“ú–{–òŠw‰ï‘æ133”N‰ïi‰¡•lj@2013.3.28

Šâú±ˆ»”TA‚‹´Ø•áAŽO‘î—çŽqA“c’†Œ’‘¾A¡ˆäŒö]A’†¼–M•v

 

ƒvƒ‰ƒoƒXƒ^ƒ`ƒ“ƒiƒgƒŠƒEƒ€‚ÌH•¨‘@ˆÛ‚Ö‚Ì‹z’…

‘æ22‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiVŠƒj@2012.10.28

ãŠÔ ÂAŠâú±ˆ»”TA¡ˆäŒö]A’†¼–M•v

 

Comparison of the contamination levels on the exterior surface of the vials containing platinum anticancer drugs among the pharmaceutical products.

FIP World Centennial Congress 2012 of Pharmacy and Pharmaceutical Sciences (Amsterdam, The Netherlands)  Oct  2012.

Naito T, Osawa T, Suzuki N, Goto T, Takada A, Nakamichi H, Onuki Y, Imai K, Nakanishi K, Kawakami J

 

ƒŠƒ|Ž_AƒRƒGƒ“ƒUƒCƒ€Q10‚̃VƒNƒƒfƒLƒXƒgƒŠƒ“•¡‡‘̗̂n‰ð«‹y‚у}ƒEƒX‚̉^“®«‚ւ̉e‹¿

‘æ29‰ñƒVƒNƒƒfƒLƒXƒgƒŠƒ“ƒVƒ“ƒ|ƒWƒEƒ€i“Œ‹žj@2012.9.7

’†¼–M•vA’†–ì^‹IŽqAã–{L•FAŠâú±ˆ»”TAŽ›”öŒ[“ñA’†“c‘å‰îA¡ˆäŒö]

 

ƒAƒXƒ^ƒLƒTƒ“ƒ`ƒ“ŠÜ—L–û‚̉^“®”\—ÍŒüã‚ɑ΂·‚éƒVƒNƒƒfƒLƒXƒgƒŠƒ“‚ÌŒø‰Ê

‘æ29‰ñƒVƒNƒƒfƒLƒXƒgƒŠƒ“ƒVƒ“ƒ|ƒWƒEƒ€i“Œ‹žj@2012.9.7

’†“c‘å‰îA¶“c’¼ŽqA㊗F‹LŽqAŽ›”öŒ[“ñAŠâú±ˆ»”TA¡ˆäŒö]A’†¼–M•v

 

“ú–{‚É‚¨‚¯‚éƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“»Ü‚̃oƒCƒAƒ‹•\–ʉ˜õ‚Ì”äŠr

‘æ20‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€i•Ÿ‰ªj 2012.7.14

‘åàV—²ŽuA“à“¡—²•¶A—é–Ø’¼ÆAŒã“¡•q–çA‚“c WA’†“¹G“¿A‘åŠÑ‚悵ŽqA¡ˆäŒö]A’†¼–M•vAìトê

 

ƒ}ƒEƒX‚̉^“®”\—͂ɋy‚Ú‚·ƒAƒXƒ^ƒLƒTƒ“ƒ`ƒ“‹y‚уrƒ^ƒ~ƒ“E‚Æ‚»‚̃VƒNƒƒfƒLƒXƒgƒŠƒ“•¡‡‘̂̉e‹¿

“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yj@2012.3.31

’†¼–M•vA”’ˆä@ŠoA’Ò@ˆŸ‹IAŠâú±ˆ»”TA¡ˆäŒö]

 

“œ”A•aŽ¡—Öòƒuƒzƒ‹ƒ~ƒ“‚ÌH•¨‘@ˆÛ‚Ö‚Ì‹z’…

“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yj@2012.3.31

Šâú±ˆ»”TA’†ì‚݂ȂÝA¡ˆäŒö]A’†¼–M•v

 

ƒeƒIƒtƒBƒŠƒ“™•úù‚Ì—no«‚ÌŒo”N•ω»

“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yj@2012.3.29

¡ˆäŒö]A’ç”V–¾”üAŠâú±ˆ»”TA’†¼–M•v

 

ƒ[ƒ„ƒ‹ƒ[ƒŠ[‚Ì5-FU—U”­Œû“à‰ŠŽ¡–ü‘£iŒø‰Ê‚Æì—pŽ÷˜‚ÌŒŸ“¢

‘æ64‰ñ“ú–{–ò—Šw‰ï¼“ì•”‰ïi•Ÿ‰ªj@2011.11.20

“nç³^ˆêA•’qŒ¤ŽuA‰Á’nO–¾A¡ˆäŒö]A––ŠÛŽ–îAr–Ø”Ž—z

 

ƒAƒ“ƒMƒIƒeƒ“ƒVƒ“‡UŽó—e‘ÌhR–ò‚ÌH•¨‘@ˆÛ‚Ö‚Ì‹z’…

‘æ21‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi_ŒËj@2011.10.1

Šâú±ˆ»”TA‚‹´˜aаAਛ‰@—BA“c’†Œ’‘¾A¡ˆäŒö]A’†¼–M•v

 

2f|ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚̃}ƒEƒX”’ŒŒ•aP388‚¨‚æ‚Ñdoxorubicine‘Ï«P388×–E‘B—}§ì—p

“ú–{–òŠw‰ï‘æ131”N‰ïiɪj@2011.3.29

Šâú±ˆ»”TA¡ˆäŒö]A’†¼–M•vA‹g‰ª³‘¥

 

ƒ‰ƒWƒJƒ‹Á‹Žì—p‚ð—L‚·‚鉻‡•¨MC-29‚Ì—n‰ð«‰ü‘P

“ú–{–òŠw‰ï‘æ131”N‰ïiɪj@2011.3.29

¡ˆäŒö]A’†¼–M•vA‘å쌴@³A—އ@‹ª

 

ƒƒTƒ‹ƒ^ƒ“ƒJƒŠƒEƒ€‚ÌH•¨‘@ˆÛ‚Ö‚Ì‹z’…

‘æ20‰ñ“ú–{ˆã—ÖòŠw‰ïi–‹’£j@2010.11.14

Šâú±ˆ»”TA“c’†Œ’‘¾A‚‹´˜aаAਛ‰@—BA¡ˆäŒö]A’†¼–M•v

 

ƒVƒNƒƒfƒLƒXƒgƒŠƒ“‚É‚æ‚é“ï—n«‰»‡•¨MC-29‚Ì—n‰ð«‰ü‘P‚ƃ‰ƒWƒJƒ‹Á‹Žì—p‚ɂ‚¢‚Ä

‘æ60‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïi‘åãj@2010.10.30

”’ˆä@ŠoA’Ò@ˆŸŠóA’ç”V–¾”üA‘º–ØGsAˆî—t–ƒˆßA’·‰ªçˆ¤A¡ˆäŒö]A’†¼–M•v

 

Effect of L-Carnitine alone,Lipoic Acid and Coenzyme Q10 with ƒÁ-Cyclodextrin Complexes on Swimming Endurance of Mice

The 15th International Cyclodextrins Symposium(Vienna)@2010.5.9-12

Kunio Nakanishi, Kimie Imai, Daisuke Nakata, and Keiji Terao

 

2f|ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚̃}ƒEƒX”’ŒŒ•aP388×–E‘B—}§ì—p

“ú–{–òŠw‰ï‘æ130”N‰ïi‰ªŽRj@2010.3.28

Šâú±ˆ»”TA“¡ˆä–ƒˆßŽqA‘ºˆä”ügAŽ›‘º‘‹MA¡ˆäŒö]A’†¼–M•vA‹g‰ª³‘¥

 

”’‹àR‚ª‚ñ–ò‚̃oƒCƒAƒ‹•\–ʉ˜õ‚Ì”÷—Ê•ªÍ–@‚ÌŠJ”­‚ƻܕiŽ¿‚Ì•]‰¿

‘æ19‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi’·èj@2009.10.25

—é–Ø’¼ÆA“à“¡—²•¶A¼–{ Œ\ŽiA‚‰È ‰ÃÍAŠÛŽR CŽ¡A‚ˆä L•FAŽR–{ ’mL@¡ˆäŒö]A’†¼–M•vAìトê

 

ŠO—pˆê”Ê—pˆã–ò•i‚Ì“Y•t•¶‘‚É‚¨‚¯‚鬎™—p—ʂ̋LÚ‚ÉŠÖ‚·‚é’²¸Œ¤‹†

‘æ19‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi’·èj@2009.10.24

¡ˆäŒö]A‰ÆŽsŽÑDA—é–Ø’¼ÆAŠâú±ˆ»”TA’†¼–M•v

 

2f|ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚Æ—Þ‰‘ÌR‚ª‚ñܓЗ^‚É‚æ‚éƒ}ƒEƒXˆÚASP2/0ƒ~ƒGƒ[ƒ}×–E‚Ì‘B—}§

“ú–{–òŠw‰ï‘æ129”N‰ïi‹ž“sj@2009.3.28

Šâú±ˆ»”TA¡‰ªƒˆêA¡ˆäŒö]A’†¼–M•vA‹g‰ª³‘¥

 

ƒ}ƒEƒX‚̉^“®”\—͂Ȃç‚тɃqƒg‚̔畆Çó‚ɑ΂·‚écoenzyme Q10-ƒÁ-ƒVƒNƒƒfƒLƒXƒgƒŠƒ“•¡‡‘̂̌ø‰Ê‚ɂ‚¢‚Ä

‘æ18‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiŽD–yj@2008.9.21

’†¼–M•vA—é–Ø’¼ÆA¡ˆäŒö]A’†“c‘å‰îAŽ›”öŒ[“ñ

 

ƒeƒIƒtƒBƒŠƒ“™•úù‚Ì•iŽ¿‚ÌŒŸ“¢

‘æ18‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiŽD–yj@2008.9.20

¡ˆäŒö]A•y“c^‰›Aà_“c—ŒbŽqA—é–Ø’¼ÆAŠâú±ˆ»”TA’†¼–M•v

 

2f|ƒfƒIƒLƒVƒVƒ`ƒWƒ“Ö¬“à“Š—^‚É‚æ‚éSP2/0ƒ~ƒGƒ[ƒ}×–EˆÚAƒ}ƒEƒX‚̉„–½

“ú–{–òŠw‰ï‘æ128”N‰ïi‰¡•lj@2008.3.27

ŠpŽRˆ»”TAX“c_”üA‹g‰ª³‘¥

 

“àˆö«2f|deoxycytidine‚Ìin vitro‚¨‚æ‚Ñin vivoŠà×–E—}§‹@\

“ú–{ŠwpU‹»‰ï‘æ‚P‚P‚UˆÏˆõ‰ï@‡“¯•ª‰È‰ïi“Œ‹žj@2008.1.16

‹g‰ª³‘¥AŠpŽRˆ»”T

 

V‹KRŽ_‰»Ügallic acid —U“±‘Ì‚¨‚æ‚Ñ carbohydrazide —U“±‘̂̊J”­

‘æ‚Q4‰ñ“ú–{–òŠw‰ï‹ãBŽx•”‘å‰ïi•Ÿ‰ªj@2007.12.9

¬“cŒ´—RA•l–{@‘¥A¡ˆäŒö]A‘å’ˉ떤A‘å쌴@³

 

2f|deoxycytidine(dCyd)‚É‚æ‚邪‚ñ‚ÌŽ¡–ü‹@\‚̉ð–¾|×–E‘B—}§ŒŸo–@‚Ì”äŠr

‘æ‚S‚V‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ïi‘åãj@2007.11.24

ŠpŽRˆ»”TA‰|–{•‡–¢ŽqA’rã—R—˜ŽqA‹g‰ª³‘¥

 

‘å’°‚ª‚ñ‰»Šw—Ö@iFOLFOX, FOLFIRI —Ö@j‚É‚¨‚¯‚é–òÜŽt‚ÌŠÖ‚í‚è

‘æ17‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‘O‹´j@2007.9.30

ŽR’†T–çA’JŒûŒ«“ñA’†¼–M•vA¡ˆäŒö]A‘å‹´NŽqAΓc—FŽqA–k‰ªˆÉ‹vŽqA•Ÿ‰i_–ç

 

‚U”N§–òŠw‹³ˆç‚É‚¨‚¯‚é‚P”N¶‚Ì“±“ü‹³ˆç‚Æ‚µ‚Ă̊î‘bŽÀK‚ÌŒŸØ

“ú–{–òŠw‰ï‘æ127”N‰ïi•xŽRj@2007.3.30

¡ˆäŒö]Aˆäã’¼lAŽñ“¡@½AŽR–{iŽqAVŒF™BŽ¡A‹ê‰Ã‹³A‰vì@“OA’†¼–M•vA‘Š–{‘¾“•v

 

V‹KRŽ_‰»ÜƒJƒ‹ƒ{ƒqƒhƒ‰ƒWƒh—U“±‘Ì‹y‚Ñ–vHŽqŽ_—U“±‘̂̊J”­

“ú–{–òŠw‰ï‘æ127”N‰ïi•xŽRj@2007.3.30

¬“cŒ´—RAà_–{@‘¥AˆÀŠyŒ’ìA¡ˆäŒö]A‘å’ˉ떤A‘å쌴@³

 

Histone deacetylase—}§Ü‚Æ‚µ‚Ă̓àˆö«2f|deoxycytidine‚ÌŽîá‡×–E‘B‚ւ̉e‹¿

“ú–{–òŠw‰ï‘æ127”N‰ïi•xŽRj@2007.3.29

ŠpŽRˆ»”TAŠC“c—T”üA‹g‰ª³‘¥

 

ƒZƒ~ƒJƒ‹ƒoƒWƒh‚¨‚æ‚уwƒeƒŠÂ—U“±‘Ì‚ÌRŽ_‰»ì—p

‘æ23‰ñ“ú–{–òŠw‰ï‹ãBŽx•”‘å‰ïiŒF–{j@2006.12.10

¬“cŒ´—RA•l–{@‘¥A¡ˆäŒö]A‘å’ˉ떤A‘å쌴@³

 

“àˆö«2f|deoxycytidine‚É‚æ‚é§Šà‹@\‚̉ð–¾

‘æ17‰ñ“ú–{—Õ°‰»Šw‰ï‹ß‹EŽx•”‘‰ïi‘åãj@2006.12.9

ŠpŽRˆ»”TA‹g‰ª³‘¥

 

Is histone deacetylase a target of 2f-deoxycytidine as endogenous anti-cancer substance?

The 116th Committee Japan Society for the Promotion of Science i“Œ‹žj@2006.11.20

‹g‰ª³‘¥AŠpŽRˆ»”T

 

ƒ}ƒEƒXƒ~ƒGƒ[ƒ}×–E‚É‚¨‚¯‚é5-fluorouracil‚Ìapoptosis‚ɑ΂·‚é2f-deoxycytidine‚Ìì—p

‘æ65‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ïi‰¡•lj@2006.9.30

ŠpŽRˆ»”TA‹g‰ª³‘¥

 

“àˆö«2f-ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚̃qƒXƒgƒ“ƒfƒAƒZƒ`ƒ‰[ƒ[‚ð‰î‚·‚éŠà—}§‹@\

‘æ19‰ñƒoƒCƒIƒƒfƒBƒJƒ‹•ªÍ‰ÈŠwƒVƒ“ƒ|ƒWƒEƒ€i•Ÿ‰ªj@2006.8.3

ŠpŽRˆ»”TA‰Í–ì–F”üA—é–Ø–]”üA’·‰À“ß”üA‹g‰ª³‘¥

 

èI‹„‚ªŠˆ«Ž_‘f‚É‹y‚Ú‚·Œø‰Ê

‘æ55‰ñ‘S“ú–{èI‹„Šw‰ïŠwp‘å‰ïi‹à‘òj@2006.6.17

‘åX@–LA¼X–¾‘¥A–kˆä‰p•FA¥Î–FGA•Ä“c‹M¶Aˆäã‰xŽqA¡ˆäŒö]A‘Š–{‘¾“•v

 

“àˆö«§Šà•¨Ž¿2f-ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚Ìì—p“_‚̓qƒXƒgƒ“ƒfƒAƒZƒ`ƒ‰[ƒ[‚©H

‘æ116ˆÏˆõ‰ïŠwpU‹»‰ïi“Œ‹žj@2006.6.5

‹g‰ª³‘¥AŠpŽRˆ»”TA‰Í–ì–F”ü

 

Œ’NH•i‚ÌŽg—pŽÀ‘Ô’²¸‚¨‚æ‚шã–ò•i‚Ƃ̕¹—p‚ÉŠÖ‚·‚錟“¢ \‹ß‹E’n‹æ“à•ÛŒ¯–ò‹Ç‚É‚¨‚¯‚éƒAƒ“ƒP[ƒg’²¸‚©‚ç\

“ú–{–òŠw‰ï‘æ126”N‰ïiå‘äj@2006.3.29

“nç³^ˆêAˆäã’¼lA¡ˆäŒö]A––ŠÛŽ–îAr–Ø”Ž—zA‘Š–{‘¾“•v

 

2f-ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚ÌŽîá‡×–Ehistone deacetylase (HDAC) Šˆ«—}§

“ú–{–òŠw‰ï‘æ126”N‰ïiå‘äj@2006.3.28

ŠpŽRˆ»”TA‰Í–ì–F”üA‹g‰ª³‘¥

 

’SŠàƒ}ƒEƒX‘ŸŠí’†2f-ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚̃Œƒxƒ‹‚ÆŠà‚Ì‘B‚Ƃ̊֌W

‘æ116ˆÏˆõ‰ïŠwpU‹»‰ïi“Œ‹žj@2006.1.16

‹g‰ª³‘¥AŠpŽRˆ»”TA‹gìç“Þ”ü

 

Šà‚̃oƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ä‚Ì2f-ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚Í“àˆö«§Šà•¨Ž¿‚©H

‘æ16‰ñ“ú–{—Õ°‰»Šw‰ï‹ß‹EŽx•”‘‰ïi‘åãj@2005.12.17

ŠpŽRˆ»”TA‹gìç“Þ”üA‹g‰ª³‘¥

 

ˆã–ò•i‚ÆH•¨‘@ˆÛ‚Ì‘ŠŒÝì—p \ƒCƒ~ƒvƒ‰ƒ~ƒ“‚ƃAƒ‹ƒMƒ“Ž_ƒiƒgƒŠƒEƒ€•¹—p‚É‚æ‚é‰e‹¿\

‘æ15‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‰ªŽRj@2005.10.1

“nç³^ˆêAˆäã’¼lA¡ˆäŒö]A––ŠÛŽ–îAr–Ø”Ž—zA‘Š–{‘¾“•v

 

’SŠàƒ}ƒEƒX‘ŸŠí’†2f-deoxycytidine‚Ì‘ª’è

‘æ64‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ïiŽD–yj@2005.9.15

ŠpŽRˆ»”TA‹g‰ª³‘¥

 

2f-ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚ÌŠà‚̃oƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ă̈Ӌ`

‘æ18‰ñƒoƒCƒIƒƒfƒBƒJƒ‹•ªÍ‰ÈŠwƒVƒ“ƒ|ƒWƒEƒ€iɪj@2005.8.6

ŠpŽRˆ»”TA‹gìç“Þ”üA‹g‰ª³‘¥

 

ƒ¿ƒVƒNƒƒfƒLƒXƒgƒŠƒ“‚ÌRƒAƒŒƒ‹ƒM[ì—p

ƒVƒNƒƒfƒLƒXƒgƒŠƒ“Šw‰ï@2005.9.1

’†“c‘å‰îA¬¼^—RŽqAŽ›”öŒ[“ñA㊗R‹LŽqA’†¼–M•v

 

5-ƒtƒ‹ƒIƒƒEƒ‰ƒVƒ‹‚ÆÃ–¬“à“¯Žž“Š—^‚µ‚½2f-ƒfƒIƒLƒVƒVƒ`ƒWƒ“‚Ì’SŠàƒ}ƒEƒX‚ł̊·ŽZŽîá‡d—ʂ̑‰Á

“ú–{–òŠw‰ï‘æ125”N‰ïi“Œ‹žj@2005.3.29

ŠpŽRˆ»”TA‹gìç“Þ”üA‹g‰ª³‘¥

 

Šw¶‚ªŠ´‚¶‚½ŽÀ–±ŽÀK‚É‚¨‚¯‚é–â‘è“_‚ƉðŒˆô

“ú–{–òŠw‰ï‘æ125”N‰ïi“Œ‹žj@2005.3.30,31

ˆäã’¼lA¡ˆäŒö]A‘Š–{‘¾“•v

 

ƒ‰ƒbƒg”]‚¨‚æ‚Ñt‚É‚¨‚¯‚éƒjƒgƒƒLƒVƒhƒ‰ƒWƒJƒ‹‚Ì“®‘Ô‰ðÍ

“ú–{–òŠw‰ï‘æ125”N‰ïi“Œ‹žj@2005.3.30

ˆäã’¼lA•¿ìŒ\‘¾A‰Á“¡‹±—TA¡ˆäŒö]A‘Š–{‘¾“•v

 

ˆã–ò•i‚ÆH•¨‘@ˆÛ‚Ì‘ŠŒÝì—p @@In vitro ‚É‚¨‚¯‚éˆã–ò•i‚ÌH•¨‘@ˆÛ‚Ö‚Ì‹z’…

“ú–{–òŠw‰ï‘æ125”N‰ïi“Œ‹žj@2005.3.29

“nç³^ˆêA–å˜e—SŽqA‹T“c”ü•ÛAŽR˜H˜a•FAˆäã’¼lA¡ˆäŒö]A‘Š–{‘¾“•vA––ŠÛŽ–îAr–Ø”Ž—z

 

ƒtƒFƒjƒ‹ƒKƒƒCƒ‹ƒAƒ~ƒh‚̃gƒ|ƒCƒ\ƒƒ‰[ƒ[‘jŠQì—p‚ÆRŽ_‰»ì—p

‘æ21‰ñ“ú–{–òŠw‰ï‹ãBŽx•”‘å‰ïi’·èj@2004.12.12

—é–ØŒ[‘¾˜YA‘å쌴@³A¡ˆäŒö]Aƒ‚ƒnƒƒhEƒAƒuƒfƒ‹EƒIƒXƒ}ƒ“A‘å’ˉ떤

 

ŽÀ–±ŽÀKŽ–‘O‹³ˆç‚ð‚ǂ̂悤‚És‚Á‚Ä‚¢‚é‚©

‘æ14‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiç—tj@2004.10.16-17

ˆäã’¼lA¡ˆäŒö]A‘Š–{‘¾“•v

 

ˆã–ò•i‚̈ùH•¨‚Ƃ̬‡‚É‚æ‚镪‰ð

\ƒGƒXƒeƒ‹Œ‹‡‚ð—L‚·‚éˆã–ò•i‚ƃˆ[ƒOƒ‹ƒgAй‹kŒnƒWƒ…[ƒX‚Ì‘g‡‚¹[

“ú–{–òŠw‰ï‘æ124”N‰ïi‘åãj@2004.3.30

“nç³^ˆêAã–칌bŽqAˆäã’¼lA¡ˆäŒö]A‘Š–{‘¾“•v

 

 

–ß‚é